Download PDF
Dialyse aktuell 2016; 20(S 01): s13-s17
DOI: 10.1055/s-0042-121663
Dialyse
© Georg Thieme Verlag Stuttgart · New York

Kalzium, Phosphatbinder und Vitamin D - Rolle in der Therapie von Dialysepatienten

Calcium, phosphate binders and vitamin D – Role in therapy of dialysis patients
Margret Patecki
1   Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover (Abteilungsdirektor: Prof. Dr. Hermann Haller)
,
Jan T Kielstein
2   Medizinische Klinik V, Städtisches Klinikum Braunschweig(Chefarzt: Prof. Dr. Jan T. Kielstein)
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2016 (online)

Also available at
    Permissions and Reprints

Sie sind für gut die Hälfte der Tablettenlast unserer Dialysepatienten verantwortlich, sind groß, schmecken bestenfalls neutral oder wie direkt aus der Aromenschmiede eines Süßwarenherstellers – gemeint sind die Phosphatbinder. Zusammen mit Vitamin D und Kalzium stehen sie im Zentrum der Therapie eines Krankheitskomplexes, der unter dem Namen CKD-MBD („chronic kidney disease – mineral and bone disorder“) firmiert. Noch unpopulärer als die o. g. Gruppen von Präparaten sind die additiven oder gar alternativen Therapiestrategien, wie die längere und effizientere Dialyse oder die leider nicht als N1-Packung verfügbare (wiederholte) Ernährungsberatung der Patienten oder der Krankenhausküchen. In dem vorliegenden Artikel sollen insbesondere die neuen Aspekte der kurz vor der Publikation stehenden KDIGO 2016 „Clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD“ stehen. Darüber hinaus werden aber auch Themen wie die Renaissance der Knochenbiopsie zur Diagnose und Therapie von CKD-MBD adressiert.

They represent about 50 % of the pill burden of patients undergoing chronic dialysis treatment (CKD 5D), they are big, taste neutral at best, but sometimes like straight from the aroma lab of a candy store – phosphate binders. Together with vitamin D and calcium, they are the main pillars of the CKD-MBD (chronic kidney disease – mineral and bone disorder) treatment. There are only 2 things less appealing than the afore mentioned drugs – longer and more efficient dialysis hours and repeated dietary counselling, even though these 2 things might be as efficient as all the pharmacological interventions. The paper at hand will focus on the forthcoming 2016 Clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD. Further, the renaissance of the good old bone biopsy for the diagnosis and therapy guidance of CKD-MBD are addressed.

Key words

calcium - phosphate binders - vitamin D - dialysis - CKD-MBD
 

  • Literatur

  • 1 Kestenbaum B, Sampson JN, Rudser KD et al Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
    CrossrefGoogle Scholar
  • 2 Gutierrez O, Isakova T, Rhee E et al Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
    CrossrefGoogle Scholar
  • 3 Eddington H, Hoefield R, Sinha S et al Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 2251-2257
    CrossrefGoogle Scholar
  • 4 Gutierrez OM, Mannstadt M, Isakova T et al Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
    CrossrefGoogle Scholar
  • 5 Larsson TE, Olauson H, Hagstrom E et al Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010; 30: 333-339
    CrossrefGoogle Scholar
  • 6 Palmer SC, Gardner S, Tonelli M et al Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis 2016; 68: 691-702
    CrossrefGoogle Scholar
  • 7 KDIGO 2016 clinical practice guidelines update on diagnosis, evaluation, prevention and treatment of CKD-MBD. Public review draft version 08/2016
    Google Scholar
  • 8 Navaneethan SD, Palmer SC, Vecchio M et al Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 16.02.2011 2. CD006023
    Google Scholar
  • 9 Ritz E, Hahn K, Ketteler M et al Phosphate additives in food - a health risk. Dtsch Arztebl Int 2012; 109: 49-55
    PubMedGoogle Scholar
  • 10 Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002; 17 (Suppl.) (2) 21-24
    Google Scholar
  • 11 Karavetian M, Ghaddar S. Nutritional education for the management of osteodystrophy (nemo) in patients on haemodialysis: a randomised controlled trial. J Ren Care 2013; 39: 19-30
    Google Scholar
  • 12 Lorenzen JM, Thum T, Eisenbach GM et al Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters. Int Urol Nephrol 2012; 44: 883-890
    CrossrefGoogle Scholar
  • 13 Bolland MJ, Barber PA, Doughty RN et al Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-266
    CrossrefGoogle Scholar
  • 14 Xiao Q, Murphy RA, Houston DK et al Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med 2013; 173: 639-646
    CrossrefGoogle Scholar
  • 15 Thadhani R, Appelbaum E, Pritchett Y et al Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
    CrossrefGoogle Scholar
  • 16 Wang AY, Fang F, Chan J et al Effect of paricalcitol on left ventricular mass and function in CKD - the OPERA trial. J Am Soc Nephrol 2014; 25: 175-186
    CrossrefGoogle Scholar
  • 17 Alem AM, Sherrard DJ, Gillen DL et al Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399
    CrossrefGoogle Scholar
  • 18 Ball AM, Gillen DL, Sherrard D et al Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-3018
    CrossrefGoogle Scholar
  • 19 Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17: 3223-3232
    CrossrefGoogle Scholar
  • 20 Lin ZZ, Wang JJ, Chung C et al Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan National Cohort Study. Bone 2014; 64: 235-239
    CrossrefGoogle Scholar
  • 21 Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44: 672-679
    CrossrefGoogle Scholar
  • 22 Iimori S, Mori Y, Akita W et al Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351
    CrossrefGoogle Scholar
  • 23 Naylor KL, Garg AX, Zou G et al Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 2015; 10: 646-653
    CrossrefGoogle Scholar
  • 24 Moe S, Drueke T, Cunningham J et al Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
    CrossrefGoogle Scholar
  • 25 Priemel M, von DC, Klatte TO et al Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010; 25: 305-312
    CrossrefGoogle Scholar
  • 26 Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26: 1368-1376
    CrossrefGoogle Scholar
  • 27 Sprague SM, Bellorin-Font E, Jorgetti V et al Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67: 559-566
    CrossrefGoogle Scholar